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ABSTRACT 
Objective: Pharmacokinetic evaluation of Dimethyl Fumarate (DMF) in the Iranian population wasn’t studied. So, the aim of this research is the 
validation of the analytical method and evaluation of the pharmacokinetic properties and bioequivalence of the generic form of this drug versus the 
reference product. 
Methods: 2 single-dose, test, and reference DMF products were orally administered to 24 healthy volunteers. The washout period was 28 d 
between the treatments. Monomethyl fumarate as the metabolite of DMF was analyzed by liquid chromatography-tandem mass spectrometry (LC-
MS/MS) and the method was validated. Also, the pharmacokinetic parameters were calculated for bioequivalence evaluation. 
Results: The analytical method was validated and linear over the range of 31.25-4000 ng/ml (R2
Conclusion: The applied analytical method is selective, accurate, precise, and repeatable for the analysis of monomethyl fumarate (MMF) in plasma. 
Also, the bioequivalence study showed no significant difference between the pharmacokinetic parameters of these 2 products. So, the DMF test 
product can be claimed to be bioequivalent with the reference product. 
= 0.997). In addition, the method was precise and 
accurate in the low, medium, and high concentrations. The results indicated that the 2 products had similar pharmacokinetics. Further, the 90% CI 
of the mean ratios of the test versus the reference products of the log-transformed area under the concentration-time curve over 10 h (0.99 to 1.02) 
and peak concentration (0.98 to 1.03) were within the acceptable range of 0.8 to 1.25 and the generic product of DMF could be similar to that of the 
reference product. 
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INTRODUCTION 
Multiple sclerosis (MS) is a chronic autoimmune, inflammatory 
neurological disease of the central nervous system (CNS) [1] that 
attacks and destroyed the myelinated axons [2]. Most of the MS 
patients (80–85%) have a Relapsing-Remitting Multiple Sclerosis 
(RRMS) disease form [3]. Treatment options in RRMS have increased 
to a dozen different available disease-modifying medicines and a few 
more are expected to be marketed soon [4]. 
Dimethyl fumarate (DMF), also known as BG-12, is the first-line oral 
treatment for RRMS [5] and has immunomodulatory properties [6]. 
DMF was approved for the treatment of psoriasis in 1959 [7] and got 
approved under the brand name of Tecfidera®
DMF is rapidly metabolized in the gastrointestinal tract into the 
primary active metabolite monomethyl fumarate (MMF) [10]. For 
this reason, DMF is not detectable in plasma after oral 
administration, and pharmacokinetics measurements are based on 
MMF concentrations [11]. MMF is dose-proportional over with high 
inter-subject variability [12]. Protein binding and volume 
distribution of MMF are 27-45% and 53-73 L, respectively [13]. By 
attention to this note that DMF microtablets in the capsules have an 
enteric coating, absorption has a delay leaving the stomach [3]. So, 
The reported time to peak concentration (T
 for the treatment of 
RRMS in 2013 [8]. DMF may cause anti-inflammatory and 
cytoprotective activities that are mediated by the nuclear factor 
(erythroid-derived 2)-like 2 (Nrf2) antioxidant response pathway [9]. 
max) of MMF after oral 
administration of Tecfidera® capsules is 2–2.5 h and the half-life of 
MMF is around 1h [14]. Also, the maximum concentration (Cmax) of 
MMF was 1.87 mg/l [14]. An administration of DMF with food delays 
the time to reach the Cmax of MMF up to 5.5h and causes a 40% 
decrease in Cmax but no effect on Area under the curve (AUC) [15]. 
Based on the above discussion, the current single-dose, 2-sequence, 
and crossover randomized study was designed to compare the 
bioequivalence of the Dimethyl fumarate formulation by Zistdaru 
Danesh Pharmaceutical Company (Teczifuma® 240 mg) as the test 
and Tecfidera®
MATERIALS AND METHODS 
 240 mg as the reference in 24 healthy Iranian 
(male/female) volunteers. 
Subjects 
The protocol of this study was approved by the Ethics Committee of 
Islamic Azad university-Damghan branch, code: IR. IAU. DAMGHAN. 
REC.1398.004 and was registered in Iranian Registry Clinical Trials 
(IRCT), IRCT ID: IRCT20200623047902N1. Additionally, written 
informed consent was obtained from all volunteers before their 
enrollment. The enrolled volunteers included 14 healthy men and 10 
healthy, non-pregnant women with a mean age of 34±5 y (range of 23-
43 y), a mean body weight of 75±18 kg (range of 47-110 kg), and a mean 
height of 173±12 cm (ranging from 151 to 197 cm). Based on the results 
of the completed clinical assessment, serum biochemistry, hematology, 
and routine urinalysis, all subjects were found to be healthy. 
Drug administration and sample collection 
The present single-dose, randomized, 2-treatment and 2-period 
crossover study was conducted on healthy Iranian male/female 
volunteers. The test or reference drug was randomly administered 
in a 1:1 ratio. In addition, all volunteers were fasted at least 10 h 
before drug administration up to 4 h after that. On the day of the test 
offered a single oral dose of reference and test formulations with 
240 ml of water. The washout period was 4 w. A total of 15 blood 
samples was collected before, 0.5, 0.75, 1, 1.5, 1.75, 2, 2.5, 3, 4, 5, 6, 7, 
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8, and 10 h after drug administration. A catheter was placed in an 
outer vein and blood samples were collected in tubes containing 
disodium-EDTA as an anticoagulant. The collected blood samples 
were then immediately centrifuged, and the plasma was separated 
and frozen at–80 °C until analysis.  
Chemical 
Acetonitrile Pro HPLC (Merck), Zinc sulfate (Sigma), Methanol Pro 
HPLC (Merck), Formic Acid (Merck). 
Sample preparation  
To preparation of the standard solution, MMF stock solution (50 µg/ml) 
and plasma were spiked and mixed at 10: 490 for 2 min. Then, the 
sample was kept without shaking for 10 min. After that, the prepared 
content was vortexed for 5 min. Then 50 µl of zinc sulfate solution (1.16 
M) and 450 µl Acetonitrile were added to the solution. The sample was 
vortexed for 5 min and then held for 10 min without shaking. Then the 
sample was centrifuged at 15 000 rpm for 10 min and the upper phase 
was separated and injected into LC-MS/MS. 
The intended standard plasma concentration range of 31.25-4000 
ng/ml was obtained through diluting the MMF standard solution 
(400 µg/ml).  
Chromatographic conditions  
Quadrupole mass spectrometer Quattro Micro (Waters-Micromass, 
UK) equipped with an electrospray source (Z-spray) was applied to 
conduct mass spectroscopy. Filtered samples were injected in a 
volume of 20 μL into a Thermo (50×4.6 mm, 5 microns) column at 
50 °C
Mass spectrometry measurements were performed on Mass Lynx 
software, version 4.1. Samples were introduced to API positive 
source values as follows: Corona 1 (uA); cone 25 V; extractor, 1 V; RF 
lens, 1 V; Source temperature: 120 °
 and separated by Alliance HT separations module 2795 
(Waters, Milford, MA, USA), which consist of a quaternary solvent 
delivery system, degasser, Autosampler, column heater. 
Chromatographic separation was performed at a flow rate of 0.5 
ml/min using an elution buffer contains 85% of eluent A (0.3% 
formic acid in water) and 15% eluent B (100% methanol). 
C; Desolvation temperature: 400 
°C; 
Validation procedure 
Desolvation gas flow rate: 500 L/h Cone gas (nitrogen 99.99% 
purity) flow rate: 150 L/h. 
Based on the Food and Drug Administration guidelines, the 
analytical method was validated in terms of linearity, range, 
specificity, accuracy, precision, and carryover [16]. 
Specificity 
The Specificity test was conducted by comparing chromatograms of 
blank plasma, plasma spiked with 1 µg/ml monoethyl fumarate 
(MEF) as internal standard (IS) and, 31.25 ng/ml MMF as the lower 
limit of quantification (LLOQ) [17]. 
Linearity  
The spiked standard solutions of MMF (in the range of 31.25-4000 
ng/ml) and MEF (1 µg/ml) as an internal standard in plasma were 
prepared and analyzed by LC-MS/MS system. The final calibration 
curves included three replicates per calibration concentration, and 
linearity was assessed by linear regression. The correlation 
coefficient of Linearity (R2
Accuracy and precision 
) should be ≥ 0.98. 
The precision and accuracy of the assay were determined from the 
low (62.5 ng/ml), medium (500 ng/ml), and high (3000 ng/ml) 
Quality Control (QC) plasma samples. The inter-day assay was 
determined by analyzing QC samples in triplicates and was analyzed 
on three different days. The intra-day precision and accuracy were 
determined for each QC sample in plasma, each in triplicate on one 
day (table 1). The precision determined at each concentration 
should not exceed 15% of the RSD%, except for LLOQ (31.25 ng/ml) 
where it should not exceed 20% of the RSD% [18]. 
Carryover effect 
During the method validation process of MMF, carryover was 
evaluated by injecting blanks, after previously injected sample with 
a concentration on Upper Level of Quantification (ULOQ) (3000 
ng/ml). 
Carryover on the blank should not be more than 20% of LLOQ and 
5% for internal standards [19].  
Stability 
Stability studies were carried out according to EMEA guidelines. 
The medium concentration (500 ng/ml) of MMF in plasma was 
prepared in triplicates and kept frozen at-80 °C
Pharmacokinetic analysis  
 until analysis. For 
short-term stability tests one-hour thaw, freeze-thaw cycles were 
studied. One-hour stability was examined by leaving plasma 
quality control samples at room temperature on the bench one 
hour before preparation. Freeze-thaw stability of the samples was 
obtained over two freeze-thaw cycles, by thawing at room 
temperature and freezing for 12-24 h for each cycle respectively. 
The concentration of MMF after each storage period was compared 
with the initial concentration that was determined for samples 
that were freshly prepared and immediately processed. The mean 
area of the stability solution should be±15% of its freshly 
prepared solution [20]. 
The standard non-compartmental procedure was applied to 
establish or calculate the pharmacokinetic parameters. Maximum 
plasma concentration (Cmax), time to reach the maximum plasma 
concentration (Tmax), area under the plasma concentration-time 
curve from time zero to the last measurable concentration (AUC0-t), 
and total area under the plasma concentration-time curve (AUC0-inf) 
were estimated from the plasma concentration-time data [21]. Cmax 
and Tmax were attained directly from the plasma data, while the 
AUC0-inf  was calculated by adding the area from time zero to last 
sampling time, t (AUC0-t), and the area from time t to infinity (AUCt-
inf). AUC0-t was calculated using the trapezoidal formula, and; AUCt-inf 
was calculated by dividing the last measurable plasma drug 
concentration (Ct) with the elimination rate constant (ke
Statistical analysis 
) [22-23].  
The values of Cmax, AUC0-t , AUC0-inf , and Tmax obtained with the two 
formulations were analyzed using the analysis of variance (ANOVA) 
procedure which differentiated effects due to subjects, periods, and 
treatments. Furthermore, AUC0-10, AUC0-inf , and Cmax were used as a 
base to evaluate the equivalence of the two formulations. The 90% 
CI of the test/reference mean ratios were determined for Cmax, AUC0–
10, and AUC0-inf
RESULTS AND DISCUSSION 
. The applicable range of 0.8 to 1.25 can lead to the 
bioequivalence between the 2 formulations. The variations between 
the 2 compared parameters were statistically significant if the P 
values were less than 0.05 [24]. 
Analytical method validation 
Specificity 
Under the chromatographic conditions described, MMF and the IS 
peaks were well resolved. Endogenous plasma components did not 
have any interfering peaks. Fig. 1 shows typical chromatograms of 
blank plasma as compare to spiked samples analyzed for a 
pharmacokinetic study. The average retention times of MMF and 
MEF were 6.2 and 2.4 min, respectively.  
Linearity  
The calibration curve (fig. 2) was linear over the mentioned range. 
The LLOQ was 31.25 ng/ml. The linearity of this method was 
statistically confirmed. For each calibration curve, the intercept 
wasn’t statistically different from zero. The correlation coefficients 
(R2) for calibration curves were adequate to or better than 0.997. 
The calibration equation is Y= 0.00154179X-0.0135467. 
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Fig. 1: Chromatograms of (A) blank plasma; (B) blank plasma 
spiked with 1 µg/ml MEF (IS) and (C) blank plasma spiked with 
31.25 ng/ml MMF 
 
Fig. 2: Calibration curve of MMF in plasma 
 
Accuracy and precision 
The precision and accuracy of the assay were determined from the 
low (62.5 ng/ml), medium (500 ng/ml), and high (3000 ng/ml) 
Quality Control (QC) plasma samples. The inter-day assay was 
determined by analyzing QC samples in triplicates and was analyzed 
on three different days. The intra-day precision was determined for 
each QC sample in plasma, each in triplicate on one day (table 1). 
The both precision value (RSD %) determined at each concentration 
wasn’t more than 8.21%. 
Accuracy was expressed as the mean percentage of analyte that 
recovered in the assay. The results of the accuracy are shown in 
table 2. As shown, coefficients of variation were less than 10%, 
which is acceptable for the routine measurement of the accuracy of 
the Bioanalytical method. 
  
Table 1: Intra-day and inter-day precision of the method for determination of MMF in human plasma 
 Concentration of MMF (ng/ml) Average of drug area/IS area±SD RSD% 
Intra-day precision 62.5 0.08±0.01 8.21 
500 0.73±0.03 4.33 
3000 4.37±008 1.92 
Inter-day precision 62.5 0.08±0.00 4.85 
500 0.75±0.00 0.57 
3000 4.42±0.09 1.96 
Note: Data given in mean±SD, n=3 
 
Table 2: Accuracy of the method for determination of MMF in human plasma 
 Concentration of MMF (ng/ml) Average of drug area/IS area±SD RSD% Deviation 
Intra-day Accuracy 62.5 0.09±0.00 4.23 -9.51 
500 0.73±0.02 2.73 3.44 
3000 4.37±0.10 2.20 5.30 
Inter-day Accuracy 62.5 0.09±0.00 0.93 -8.07 
500 0.77±0.06 7.34 -1.47 
3000 4.26±0.04 0.92 7.50 
Note: Data given in mean±SD, n=3 
 
 
Fig. 3: Carryover effect between high concentration sample of MMF and blank 
 
Carryover effect 
Carryover between samples can occur in analytical methods. But in 
this method development carryover effect was evaluated and no 
accumulation after a high concentration of MMF was seen (fig. 3). So, 
it could be concluded no need for a meaningful cleaning procedure 
between injections. 
Stability 
The stability of MMF and IS in the short term and freeze and thaw 
cycles was tested. In all of these stability studies, both MMF and IS 
did not show any significant degradation (table 4). These results 
confirmed that MMF was stable in plasma under the storage 
conditions and during sample preparation. 
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Table 4: Stability of MMF and IS in short term and freeze-thaw cycle 
 Test (Area) Standard (Area) Test/STD mean ratio  
 MMF IS MMF IS MMF IS 
Short term 
stability 
Mean 3274.3 4215.3 2967.7 3875.3 1.1 1.1 
SD 122.1 70.5 69.3 36.0   
RSD% 3.7 1.7 2.3 0.9   
Freeze and thaw 
stability 
Mean 3021.7 4215.3 2967.7 3875.3 1.0 1.1 
SD 560.3 70.5 69.3 36.0   
RSD% 18.5 1.7 2.3 0.9   
Note: data given in mean±SD, n=3 
 
As seen in the above table, there is less than a 10% difference 
between fresh standard and remained sample at room temperature 
for 1 hour and sample that passed 2 cycles of freezing and thawing. 
Pharmacokinetics 
35 subjects were screened. 24 subjects were randomized and included 
in the study. The subjects were divided into two groups according to 
the randomization table. There was one drop-out (Subject 20, because 
of fainting before drug administration of the second period). As a 
result, 23 subjects completed the study and no serious adverse effect 
was observed in any treatment. The pharmacokinetic parameters 
(mean±SD) for the test and reference products are summarised in 
table 5. The logarithmic value of CRmaxR, AUCR0-10R, and AUCR0-inf Rmeans, 
ratios, and 90% CIs are summarised in table 6. 
  
Table 5: Summary of pharmacokinetics parameters of test and reference 
Type CRmax R(ng/ml) TRmax R(h) KReR=-Slope (1/h) TR1/2R= 0.693/k (h) AUCR0-10 R(ng. h/ml) AUCR0-inf R(ng. h/ml) 
Test (n= 24) 1689.9±716.1 2.1±0.9 1.1±0.2 0.7±0.1 3194.3±1308.3 3225.3±1310.8 
Reference (n= 23) 1863±1191 2.5±0.9 1.0±0.3 0.8±0.3 3200.2±1623.4 3244.0±1621.6 
Note: Data given in mean±SD, for Test n= 24, for Reference n= 23 
 
Table 6: The logarithmic value of CRmaxR, AUCR0-10R, and AUCR0-inf Rmeans, ratios, and 90% CIs 
Parameter Formulation N mean±SD Mean test/reference ratio±SD Confidence interval 90% 
Lower Upper 
Ln CRmaxR (ng/ml) Test 23 7.33±0.46 1.00±0.07 0.98 1.03 
Reference 23 7.35±0.61 
Ln AUCR0-10 R(ng. h/ml) Test 23 7.98±0.45 1.00±0.04 0.99 1.02 
Reference 23 7.96±0.46 
Ln AUCR0-inf R(ng. h/ml) Test 23 7.99±0.44 1.00±0.04 0.99 1.01 
Reference 23 7.98±0.46 
TRmaxR (h) Test 23 2.1±0.9 0.9±0.5 - 
Reference 23 2.5±0.9 
Note: Data given in mean±SD, n=23 
 
Average plasma concentration-time curves of test and reference 
products for a single dose of DMF are shown in fig. 4. The 
reference and test formulations used in the current study have 
mean AUC R0-10 Rvalues 3200.2±1623.4 ng·h/ml and 3194.2±1308.3 
ng·h/ml, respectively. Mean C RmaxR values for the reference and the 
test formulations are 1862.7±1191 and 1686.9±716.1 ng/ml, 
respectively. Further, the mean T RmaxR values were 2.5±0.9 and 
2.1±0.9 h in reference and test formulations (table 5). A higher 
inter-subject variability in T RmaxR was observed, which is as a 
result of variability in gastric emptying time delayed release 
capsules [25]. 
The results of the t-test, demonstrate no difference between the 
average parameters that resulted from sequencing, period, and 
administering the test and reference products at the significance level 
of 0.05. The 90% CIs for the mean ratios of the test versus reference 
formulation of CRmaxR, AUCR0-10R, and AUCR0-inf Requal to 0.98-1.03, 0.99-1.02, 
and 0.99-1.01, respectively. Therefore, both are placed in an 
acceptable range of 0.80 to 1.25 and are found to be bioequivalent.
 
 
Fig. 4: MMF plasma concentration-time in healthy volunteers following consumption of Tecfidera P® P 240 mg (reference) and TeczifumaP® P 
240 mg (test) (n=23). Concentration presented based on mean±SD 
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CONCLUSION 
The optimized LC-MS/MS method is selective, accurate, precise, and 
repeatable. The method is linear over a wide range and utilizes a 
mobile phase that can be easily prepared. The run time is short and 
the protein precipitation technique is very simple. It can be 
concluded that the method is suitable for the routine quantification 
of MMF in human plasma. 
Overall, in vivo examinations of the test and reference products 
revealed no significant difference between the pharmacokinetic 
parameters of these 2 products. Accordingly, the DMF test product 
can be claimed to be bioequivalent with the reference product and 
both products were similar in terms of the rate and extent of 
absorption. Therefore, considering that test product is 
pharmaceutical equivalent and bioequivalent, indicates that both 
products are therapeutically equivalent and interchangeable. 
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